Stay updated on Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:44:54.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents the addition of 20 additional participants to the study if the combination of Pembrolizumab and PLD is well tolerated.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:57.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a more detailed description explaining that researchers look for people who fit specific eligibility criteria, such as general health condition or prior treatments. This change provides a clearer understanding of the criteria used to select participants for clinical research studies.
    Difference
    51%
    Check dated 2024-05-22T21:03:17.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:26:23.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.